Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.53 |
| ▸ | CMA1 | P23946 | 2/20 | 0.53 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.37 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1847559 | 0.93 | AHR (0.53) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL30224280 | 0.93 | AHR (0.53) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL548762 | 0.84 | AHR (0.50) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL4065845 | 0.84 | AHR (0.60) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL14780283 | 0.84 | CA9 (0.46) | AHRCMA1MAOBKIF11 | |
| SCHEMBL153860 | 0.78 | AHR (0.53) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL10368283 | 0.78 | GRIA1 (0.47) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL16050307 | 0.78 | AHR (0.53) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL16372572 | 0.78 | AHR (0.44) | AHRCMA1EIF2AK2PDK2PDE3B | |
| SCHEMBL4500799 | 0.78 | AHR (0.53) | AHRCMA1EIF2AK2PDK2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11453681-B2 | Substituted eneoxindoles and uses thereof | GILEAD SCIENCES, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| EP-3972695-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022011123-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20200392153-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2020237025-A1 | SUBSTITUTED EXO-METHYLENE-OXINDOLES WHICH ARE HPK1/MAP4K1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-20160368870-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-12-22 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1981884-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | Amgen, Inc (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084391-A2 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS | AMGEN INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368870-A1 | OLEFIN SUBSTITUTED OXINDOLES HAVING AMPK ACTIVITY | OXER1, AK2, GPR119 | AHR 958/4885CMA1 4268/4885EIF2AK2 1010/4885 |
| US-11453681-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | AHR 409/4885CMA1 3480/4885EIF2AK2 451/4885 |
| US-20230183262-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | HIPK1, HPGDS, HIPK3 | AHR 409/4885CMA1 3480/4885EIF2AK2 451/4885 |
| US-12037342-B2 | Substituted eneoxindoles and uses thereof | HIPK1, HPGDS, HIPK3 | AHR 409/4885CMA1 3480/4885EIF2AK2 451/4885 |
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | AHR 3497/4885CMA1 3601/4885EIF2AK2 387/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | AHR 2935/4885CMA1 2766/4885EIF2AK2 210/4885 |
| US-20230257396-A1 | MACROCYCLES AND THEIR USE | VHL, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DLD | AHR 574/4885CMA1 3794/4885EIF2AK2 2758/4885 |
| US-20200392153-A1 | SUBSTITUTED ENEOXINDOLES AND USES THEREOF | HIPK1, HPGDS, HIPK3 | AHR 409/4885CMA1 3480/4885EIF2AK2 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.